New Zealand’s government should not introduce special provisions for medical cannabis products as part of future plans to make it more accessible, University of Otago medical scientists have said.
Michelle Glass, head of the department of pharmacology and toxicology, and John Ashton from the university’s brain health research centre, say that medical cannabis products must meet the rigorous standards required for all other medicines.
In an editorial published in the New Zealand Medical Journal, they argue that “what is considered a medicine in the legal and pharmaceutical sense should not be changed in an ad hoc way to accommodate cannabis”.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.